Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.…
Generate Biomedicines: Q3 Earnings Snapshot
Zealand Pharma pens $1.2bn AI obesity drug discovery pact with Generate
Generate Biomedicines (NASDAQ: GENB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 312 employees.
The shares were at 9.540 USD on 20 November 2026. Its 52-week range is 9.400 USD to 22.67 USD: the price is 57.9% below the high and 1.5% above the low.
Its market capitalisation is 1.23B USD.
Generate Biomedicines reports return on equity of 33.0% and revenue down 56.2% year over year.
It holds more cash than debt, a net cash position of 328.87M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 26.80 USD is 180.9% above the current price. The next earnings report is expected on 25 March 2027.